Free shipping on all orders over $ 500

Abatacept

Cat. No. M11481

All AbMole products are for research use only, cannot be used for human consumption.

Abatacept Structure
Synonym:

CTLA4lg; BMS-188667

Size Price Availability
1mg USD 550  USD550 3-4 Weeks
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Abatacept is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1. Abatacept binds to antigen presenting cells CD80 and CD86, blocks costimulatory signals and inhibits T cell activation, and is used in the study of rheumatoid arthritis and juvenile rheumatoid arthritis.

Chemical Information
CAS Number 332348-12-6
Form Solid
Storage 4°C, protect from light, do not freeze.
References

[1] Benjamin Watkins, et al. J Clin Oncol. Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD

[2] Andrea Rubbert-Roth, et al. N Engl J Med. Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis

[3] Ayca Kiykim, et al. J Allergy Clin Immunol Pract. Abatacept as a Long-Term Targeted Therapy for LRBA Deficiency

[4] Manuel Pombo-Suarez, et al. Expert Rev Clin Immunol. Abatacept for the treatment of rheumatoid arthritis

[5] Hannah A Blair, et al. Drugs. Abatacept: A Review in Rheumatoid Arthritis

Related Fusion Proteins Products
Aflibercept

Aflibercept is a vascular epidermal growth factor (VEGF-A and PlGF) receptor inhibitor that inhibits the growth of neovascularization. It can be used to study a variety of diseases caused by ocular neovascularization.

Etanercept

Etanercept is a dimer fusion protein that binds tumor necrosis factor (TNF) as a TNF inhibitor. Etanercept competitively inhibits the binding of TNF-α and TNF-β to TNF receptors on the cell surface, rendering tumor necrosis factor biologically inactive.

Batiraxcept

Batiraxcept (AVB-S6-500) is a highly potent and specific GAS6-AXL signaling pathway inhibitor, a recombinant fusion protein dimer containing the extracellular domain of human AXLM and human immunoglobulin G1 heavy chain (Fc). Batiraxcept binds to GAS6 and inhibits the interaction of GAS6 with AXL, thereby substantially reducing AXL signaled invasion and migration of highly metastatic cells in vitro.

Sotatercept

Sotatercept (ACE-011; MK-7962) is a first-in-class activin receptor 2A (ACVR2A) type IgG Fc fusion protein. Sotatercept combines activin and growth differentiation factor to try to restore the balance between growth promotion and growth inhibition signal pathways. Sotatercept has potential application in pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, multiple myeloma (MM) osteolytic lesions.

Ramatercept

Ramatercept is a soluble ActRIIB receptor and can be used as a soluble activin receptor 2 (ACVR2) antagonist. Ramatercept inhibits the signal pathway of muscle growth inhibition and has potential application in muscle atrophy.

  Catalog
Abmole Inhibitor Catalog




Keywords: Abatacept, CTLA4lg; BMS-188667 supplier, Fusion Proteins, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.